CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
A new webpage has been created for members to access the most up-to-date ID.me information. You can now find the direct link to the ID.me updates on the CCTG website in the "Toolbox" under "Updates".
The new direct link can be found here: https://www.ctg.queensu.ca/private/member-updates/IDme if your team needs to bookmark the information.
CCTG is very happy to introduce our patient focused trial webpages that have been developed for recent CCTG trials open to patient enrollment. The goal for this content is to provide CCTG trial specific plain language information for patients and their families that can be used to enhance discussions with their health care team.
Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data
A unique, patient focused trial aims to explore if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer with a better quality of life if they start treatment earlier. If someone is diagnosed with CLL or SLL they may not have major symptoms and treatment is often started when they show symptoms such as fever, anemia, or night sweats.
CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial investigating a novel cell therapy using the immune system to treat people with relapsed and refractory multiple myeloma.
CCTG HN13 clinical trial has successfully been awarded $1,602,675 in the Spring 2023 CIHR funding competition to investigate improving head and neck tumour and symptom control in patients who are unable to tolerate curative radiotherapy.
